scholarly journals NEPHROTOXICITY FROM METHOXYFLURANE ANAESTHESIA: A 6-YEAR RETROSPECTIVE STUDY * *Supported in part by General Research Support Grant FR05372 from the General Research Support Branch, Division of Research Facilities and Resources, National Institutes of Health.

1973 ◽  
Vol 45 (4) ◽  
pp. 358-362 ◽  
Author(s):  
R.B. URGENA ◽  
S.D. GERGIS
Keyword(s):  
Retrospective Study ◽  
National Institutes Of Health ◽  
Research Support ◽  
Methoxyflurane Anaesthesia ◽  
Research Facilities

PEDIATRICS AND SOCIETY

PEDIATRICS ◽  
1960 ◽  
Vol 25 (1) ◽  
pp. 145-150
Author(s):  
Lytt I. Gardner
Keyword(s):  
Medical Research ◽  
Public Support ◽  
National Institutes Of Health ◽  
International Institute ◽  
Research Activities ◽  
The Status ◽  
Set Up ◽  
Research Facilities ◽  
And Child Health ◽  
Harvard School

THIS is a progress report to the readers of Pediatrics on the status of Senator Lister Hill's "Health for Peace" bill (Senate Joint Resolution 41). This measure, which would have set up an international institute of medical research, passed the Senate May 20, 1959 with flying colors but finally was snagged in a House subcommittee through the summer of 1959. The legislation received resounding approval by the Senate, with a vote of 63 to 17. The bill proposed to organize an Institute of International Medical Research within the framework of the National Institutes of Health. A $50,000,000 annual appropriation was planned. Evidence of widespread public support for the measure was observed in the statements of authorities who spoke at the Senate hearings concerning the bill. It is of interest that no one appeared to testify against S.J. Res. 41 during the 6 days of hearings. At lease two persons participating in the hearings were members of the American Academy of Pediatrics: Dr. Martha M. Eliot, Head, Department of Maternal and Child Health, Harvard School of Public Health and Dr. Sidney Farber (Honorary Associate Member), Professor of Pathology, Harvard Medical School. Many witnesses pointed out the importance of providing support for the research activities and the training of promising scholars in other lands. On this subject, Dr. Farber had this to say: In many countries, such as Italy, the amount of research support available is so small that men of great skill and intellect are compelled to carry on only token research concerning problems which are selected because they do not require manpower, equipment, or modern research facilities.

AB1239 THE EFFECT OF INFLUENZA VACCINATION ON THE MULTI-BIOMARKER DISEASE ACTIVITY SCORE AND ITS COMPONENT BIOMARKERS IN HEALTHY SUBJECTS

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 1910-1911
Author(s):  
D. Furst ◽  
L. Lenz ◽  
M. Horton ◽  
D. Flake ◽  
E. Sasso ◽  
...  
Keyword(s):  
Influenza Virus ◽  
Influenza Vaccine ◽  
Disease Activity ◽  
Virus Vaccine ◽  
Healthy Subjects ◽  
Influenza Virus Vaccine ◽  
National Institutes Of Health ◽  
Research Support ◽  
Myriad Genetics ◽  
Over Time

Background:The multi-biomarker disease activity (MBDA) blood test measures 12 protein biomarkers (IL-6, CRP, SAA, EGF, VEGF, VCAM, MMP-1, MMP-3, leptin, resistin, TNF-RI and YKL40). It uses a validated algorithm to provide a score on a scale of 1-100 for assessing disease activity in patients with rheumatoid arthritis (RA). The MBDA score reflects several molecular aspects of inflammation, including cytokines, acute phase reactants, growth factors, molecular adhesion, metalloproteinases and hormones. Insights gained by understanding how vaccination affects these biomarkers in healthy subjects - in whom the level of inflammation prior to vaccination should be low and stable - may aid the understanding of how vaccination affects patients with RA.Objectives:The goal of this study was to understand how immunization of healthy subjects with the influenza vaccine affects the assessment of inflammation with the MBDA score and its 12 biomarkers.Methods:A 4-strain influenza virus vaccine (Fluarix Quadrivalent, GlaxoSmithKline) was administered intramuscularly to 22 healthy volunteer subjects on October 24, 2018. Serum samples were obtained immediately prior to vaccination (baseline) and 1, 2 and 3 weeks after vaccination. No restrictions were placed on subject activity. Samples were stored at -80oC until measurement of the 12 MBDA biomarkers for determination of the adjusted MBDA score, hereafter called the MBDA score. (Adjustment accounts for the effects of age, sex and adiposity1). MBDA scores (natural scale) and biomarker concentrations (log scale) were modeled using generalized estimating equations (GEE) that account for correlations between measurements from the same subject at multiple timepoints. Significance of MBDA score change or biomarker concentration change over time was determined by a likelihood ratio test of timepoints.Results:Of the 22 healthy subjects receiving the influenza virus vaccine, 14 (63.6%) were female, with mean (SD) age of 40.0 years (8.9). MBDA scores were low (<30), moderate (30-44) or high (>44) for 15 (68%), 6 (27%) and 1 (5%) subjects at baseline, and this distribution was stable over time (Figure 1). Overall, MBDA scores did not change significantly over time (p=0.48, Figure 2). Mean changes in MBDA score (95% CI) from baseline to weeks 1, 2 and 3 were 0.32 (-3.07, 3.71), 0.82 (-3.03, 4.67) and 2.86 (-1.10, 6.82), respectively (Figure 2); the week 3 value becomes 0.95 (-1.78, 3.68) if the week 3 outlier is removed. Among the 66 post-baseline measurements of change in MBDA score (Figure 2), 3 (5%) exceeded the 95% CI for change in MBDA score in this study (i.e., 14). When assessing the entire cohort across all timepoints, EGF was the only biomarker that demonstrated statistically significant change over time (p=5.6 x 10-7). At weeks 1, 2 and 3, the mean relative concentrations of EGF, compared with baseline, were 0.62 (0.52, 0.74), 0.86 (0.70, 1.06) and 0.62 (0.50, 0.76), respectively.Figure 1Figure 2Conclusion:Immunization of 22 healthy subjects with a quadrivalent influenza vaccine did not have a statistically significant effect on MBDA scores during a 3-week observation, and it had minimal effect on the component biomarkers.References:[1]Curtis et al.Rheumatology [Oxford]2018;58:874Disclosure of Interests:Daniel Furst Grant/research support from: AbbVie, Actelion, Amgen, BMS, Corbus Pharmaceuticals, the National Institutes of Health, Novartis, Pfizer, and Roche/Genentech, Consultant of: AbbVie, Actelion, Amgen, BMS, Cytori Therapeutics, Corbus Pharmaceuticals, the National Institutes of Health, Novartis, Pfizer, and Roche/Genentech, Speakers bureau: CMC Connect (McCann Health Company), Lauren Lenz Shareholder of: Myriad Genetics, Inc., Employee of: Myriad Genetics, Inc., Megan Horton Shareholder of: Myriad Genetics, Inc., Employee of: Myriad Genetics, Inc., Darl Flake Shareholder of: Myriad Genetics, Inc., Employee of: Myriad Genetics, Inc., Eric Sasso Shareholder of: Myriad Genetics, Inc., Employee of: Myriad Genetics, Inc., Michael E. Weinblatt Grant/research support from: BMS, Amgen, Lilly, Crescendo and Sonofi-Regeneron, Consultant of: Horizon Therapeutics, Bristol-Myers Squibb, Amgen, Abbvie, Crescendo, Lilly, Pfizer, Roche, Gilead

Effects of the Cyclooxygenase Inhibiting Nitric Oxide Donator Naproxcinod Versus Naproxen on Systemic Blood Pressure in Patients With Osteoarthritis††Conflicts of interest: Dr. White reports receiving research support during the past 12 months from the National Institutes of Health, Bethesda, Maryland; the Catherine and Patrick Donaghue Medical Research Foundation, West Hartford, Connecticut; the American Heart Association, Dallas, Texas; and Novartis Pharmaceuticals Corporation, East Hanover, New Jersey. Dr. White presently serves as a safety consultant to Gilead Sciences, Inc., Foster City, California; Myriad Genetics, Inc., Salt Lake City, Utah; NicOx S.A., Sophia-Antipolis, France; Takeda Research and Development Group, Deerfield, Illinois; and Teva Neuroscience, Inc., Kansas City, Missouri. Dr. Schnitzer reports receiving research support from the National Institutes of Health; Pfizer Laboratories, Inc., New York, New York; Wyeth Laboratories, Madison, New Jersey; Nordic Bioscience, Herlev, Denmark; Novartis Pharmaceuticals Corporation; Genzyme Corporation, Cambridge, Massachusetts; and Pozen, Inc., Chapel Hill, North Carolina. Dr. Schnitzer presently serves as a consultant to Logical Therapeutics, Inc., Waltham, Massachusetts; NicOx, Inc., Warren, New Jersey; Merck & Company, Inc., Whitehouse Station, New Jersey; SantoSolve AS, Oslo, Norway; Solstice Neurosciences, South San Francisco, California; and Horizon Therapeutics, Northbrook, Illinois. Dr. Schnitzer is a noninvested shareholder of NicOx S.A. Mrs. Fleming is an employee of NicOx, Inc. Drs. Duquesroix and Beekman are employees of NicOx, S.A.

2009 ◽  
Vol 104 (6) ◽  
pp. 840-845 ◽  
Author(s):  
William B. White ◽  
Thomas J. Schnitzer ◽  
Rosanna Fleming ◽  
Brigitte Duquesroix ◽  
Maarten Beekman
Keyword(s):  
New York ◽  
New Jersey ◽  
San Francisco ◽  
Kansas City ◽  
Conflicts Of Interest ◽  
Salt Lake ◽  
Heart Association ◽  
Systemic Blood Pressure ◽  
National Institutes Of Health ◽  
Research Support
Sign in / Sign up

Export Citation Format

Share Document